Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Operating profit has grown by an annual rate 12.09% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
EUR 48,109 Million ()
21.00
NA
2.23%
0.81
13.07%
2.67
Revenue and Profits:
Net Sales:
5,662 Million
(Quarterly Results - Jun 2025)
Net Profit:
556 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.81%
0%
-17.81%
6 Months
-20.24%
0%
-20.24%
1 Year
-22.1%
0%
-22.1%
2 Years
-18.44%
0%
-18.44%
3 Years
-18.96%
0%
-18.96%
4 Years
-10.28%
0%
-10.28%
5 Years
-0.72%
0%
-0.72%
Siemens Healthineers AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.08%
EBIT Growth (5y)
11.39%
EBIT to Interest (avg)
18.12
Debt to EBITDA (avg)
2.96
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.62
Tax Ratio
24.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
9.64%
ROE (avg)
11.15%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
3.05
EV to EBIT
17.68
EV to EBITDA
13.16
EV to Capital Employed
2.19
EV to Sales
2.85
PEG Ratio
0.94
Dividend Yield
1.99%
ROCE (Latest)
12.37%
ROE (Latest)
14.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
5,662.00
5,423.00
4.41%
Operating Profit (PBDIT) excl Other Income
1,242.00
983.00
26.35%
Interest
104.00
116.00
-10.34%
Exceptional Items
-131.00
0.00
Consolidate Net Profit
556.00
472.00
17.80%
Operating Profit Margin (Excl OI)
154.00%
126.90%
2.71%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 4.41% vs 4.27% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 17.80% vs 4.66% in Jun 2024
Annual Results Snapshot (Consolidated) - Sep'24
Sep'24
Sep'23
Change(%)
Net Sales
22,363.00
21,680.00
3.15%
Operating Profit (PBDIT) excl Other Income
4,523.00
3,997.00
13.16%
Interest
476.00
296.00
60.81%
Exceptional Items
-431.00
-204.00
-111.27%
Consolidate Net Profit
1,959.00
1,525.00
28.46%
Operating Profit Margin (Excl OI)
147.60%
112.50%
3.51%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2024 is 3.15% vs -0.16% in Sep 2023
Consolidated Net Profit
YoY Growth in year ended Sep 2024 is 28.46% vs -25.75% in Sep 2023
About Siemens Healthineers AG 
Siemens Healthineers AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






